"Proton therapy" from_date:2012

Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * Year AIHTA - Publications - Search - Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer Erdos, J. and Schmidt, L. and Reinsperger, I.(2024):Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107/ 1. Update

Proton therapy for the treatment of cancer in children and adults Proton therapy for the treatment of cancer in children and adults Hoppa till textinnehållet * About * Collaboration * Impact * Other languages * Contact * Listen * På Svenska Swedish Agency for Health Technology Assessment and Assessment of Social Services * Publications * Ongoing projects * Method * Evidence gaps * Presentations at Cochrane colloquium * ImpactVisa undermeny * Does health technology assessment affect policy-making and clinical practice in Sweden? * Search evidence gaps * About * Collaboration * Impact * Other languages * Contact * Listen * På Svenska Proton therapy for the treatment of cancer in children and adultsHalf of all cancer patients receive radiotherapy at some point

Online Adaptive Proton Therapy Facilitated by Artificial Intelligence-based Auto Segmentation in Pencil Beam Scanning Proton Therapy: Prostate oAPT in PBSPT. Online adaptive proton therapy (oAPT) is essential to address interfractional anatomical changes in patients receiving pencil beam scanning proton therapy (PBSPT). Artificial intelligence (AI)-based auto-segmentation can increase

Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. We aimed to determine if ultra-hypofractionated proton therapy delivered via stereotactic body proton therapy (SBPT) is non-inferior to conventionally fractionated proton therapy (CFPT) in patients with early prostate cancer. This study

Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012-21) from the National Association for Proton Therapy. The XXXX conducted eight surveys of all operational United States proton centers (2012-2021), analyzing patients treated, diagnoses, treatment complexity, to evaluate trends and diversification of patients receiving proton therapy. Detailed surveys were sent in 2015, which requested data on 2012-2014, then annually to active proton centers in the US. Patient numbers treated at each center for the preceding calendar year(s) were collated for tumors in the following categories: central nervous system (CNS), intraocular, pituitary, skullbase/skeleton, head/neck, lung, retroperitoneal/soft tissue

Long-term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials. While definitive chemoradiation (CRT) with 5-FU/MMC remains the standard of care for localized anal cancer, treatment is associated with significant acute and late toxicity. Proton radiation therapy (RT) may potentially reduce such toxicity. Here, we assess the long-term outcomes of anal cancer patients treated with CRT using proton RT in two prospective pilot studies. Patients with stage I-III anal cancer treated with proton RT (pencil beam scanning or intensity modulated proton therapy) per RTOG 0529 dose schema with concurrent 5-FU/MMC (2 cycles) in two prospective, single-arm trials were followed. Loco-regional failure (LRF

In silico interim adaptation of proton therapy in head and neck cancer by simultaneous dose and linear energy transfer escalation. The outcome of proton therapy for head and neck cancer (HNC) varies considerably. We investigated the feasibility of adapting proton therapy plans based on F-FDG-PET-defined biologic tumor volumes (BTV) reflecting remaining aggressive tumor subvolumes two weeks into treatment (interim). Recognizing the potential to improve proton therapy response with increasing linear energy transfer (LET), we simulated a combined dose-LET escalation to the BTVs and compared it to pure dose escalation. In addition, the impact of relative biological effectiveness (RBE) was evaluated by comparing the constant RBE of 1.1 (RBE) with a variable-RBE model. A semiautomated method was used

Contrast-enhancing Lesions Induced by CNS-directed Intensity Modulated Proton Therapy: Distribution Patterns, Kinetics, Risk Factors, and Outcomes. Patients treated with intensity modulated proton therapy (IMPT) may develop intracranial radiation-induced contrast enhancement (RICE). The incidence, distribution, kinetics, predisposing factors, linear energy of transfer (LET) associations

Intensity-modulated proton therapy for hippocampal-sparing prophylactic cranial irradiation: a planning comparison with photon therapy. The purpose of the study was to evaluate the dosimetric characteristics of volumetric modulated arc therapy (VMAT), helical tomotherapy (HT), and intensity-modulated proton therapy (IMPT) and to compare the dosimetric differences between the two IMPT plans

Feasibility evaluation of N-Isopropyl Acrylamide 3D gel dosimeters for proton therapy. This study aimed to investigate the feasibility of applying 3D gel dosimeters for proton therapy. Two different formulations (5-5-3-5, 5-3-3-10) for the N-Isopropyl Acrylamide (NIPAM) polymer gel were used to find the best composition for the application of NIPAM polymer gels for proton therapy. The reaction

Thoracic Proton Minibeam Radiation Therapy: Tissue Preservation and Survival Advantage over Conventional Proton Therapy. Proton Minibeam Radiotherapy (pMBRT) is an innovative radiation therapy approach that highly modulates the spatial dimension of the dose delivery using narrow, parallel, and submillimetric proton beamlets. pMBRT has proven its remarkable healthy tissue preservation ) pMBRT or conventional proton therapy (CPT) without any respiratory control. The development of radiation-induced pulmonary fibrosis was longitudinally monitored using cone-beam computed tomography. Anatomopathological analysis was carried out at 9 months post-irradiation and focused on the reaction of the lungs' parenchyma and the response of cell types involved in the development of radiation-induced

Pencil beam scanning proton therapy for mediastinal lymphomas in deep inspiration breath-hold: a retrospective assessment of plan robustness. The aim of this study was to evaluate pencil beam scanning (PBS) proton therapy (PT) in deep inspiration breath-hold (DIBH) for mediastinal lymphoma patients, by retrospectively evaluating plan robustness to the clinical target volume (CTV) and organs

Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era. It was hypothesized that use of proton beam therapy (PBT) in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation and consolidative immune checkpoint inhibition is associated with fewer unplanned

A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry. Paucity and low evidence-level data on proton therapy (PT) represent one of the main issues for the establishment of solid indications in the PT setting. Aim of the present registry, the POWER registry, is to provide a tool for systematic, prospective, harmonized, and multidimensional high

NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy. This position paper, led by the NRG Oncology Particle Therapy Work Group, focuses on the concept of relative biologic effect (RBE) in clinical proton therapy, with the goal of providing recommendation for the next generation clinical trials with proton therapy on the best practice of investigating and using RBE to allow clinical validation and inter-patient comparisons. These concepts provide the foundation for personalized biologic treatments reviewed in part four. Finally, we conclude with a summary including short- and long-term scientific focus points for clinical proton therapy. The practicalities and capacity to use RBE in treatment planning are reviewed and considered with more biological data in hand

PTCOG Ocular Statement: Expert Summary of Current Practices and Future Developments in Ocular Proton Therapy. Although rare cancers, ocular tumors are a threat to vision, quality of life, and potentially life expectancy of a patient. Ocular proton therapy (OPT) is a powerful tool for successfully treating this disease. The Particle Therapy Co-Operative Ocular Group (PTCOG Ocular) formulated continuity of OPT will depend on (i) maintaining and upgrading existing older dedicated low-energy facilities, (ii) maintaining shared, degraded beamlines at large proton therapy centers, and (iii) developing adapted gantry beams of sufficient quality to maintain the clinical benefits of sharp beam conformity. Option (i) potentially offers the sharpest beams, minimizing impact on healthy tissues, whilst

Prospective analysis of radiation-induced contrast enhancement (RICE) and health-related quality of life following proton therapy for CNS and skull base tumors. Intracerebral radiation-induced contrast enhancement (RICE) can occur after photon as well as proton beam therapy (PBT). This study evaluated the incidence, characteristics and risk factors of RICE after PBT delivered to, or in direct

Spot-scanning proton therapy for early breast cancer in free breathing versus deep inspiration breath-hold. Proton therapy for breast cancer is usually given in free breathing (FB). With the use of deep inspiration breath-hold (DIBH) technique, the location of the heart is displaced inferiorly, away from the internal mammary nodes and, thus, the dose to the heart can potentially be reduced . The aim of this study was to explore the potential benefit of proton therapy in DIBH compared to FB for highly selected patients to reduce exposure of the heart and other organs at risk. We aimed at creating proton plans with delivery times feasible with treatment in DIBH. Sixteen patients with left-sided breast cancer receiving loco-regional proton therapy were included. The FB and DIBH plans were

Proton Therapy for Spinal Tumors: A Consensus Statement from the Particle Therapy Cooperative Group. Proton beam therapy (PBT) plays an important role in the management of primary spine tumors. The purpose of this consensus statement is to summarize safe and optimal delivery of PBT for spinal tumors. The Particle Therapy Co-Operative Group (PTCOG) Skull Base/Central nervous system (CNS)/Sarcoma

Effect of breathing phase number on the 4D robust optimization for pancreatic cancer intensity modulated proton therapy. Respiratory movement, as one of the main challenges in proton therapy for pancreatic cancer patients, could not only lead to harm to normal tissues but also lead to failure of the tumor control, resulting in irreversible consequences. Including respiratory movements into the plan optimization, i.e. 4D robust optimization, may mitigate the interplay effect. However, 4D robust optimization considering images of all breathing phases is time-consuming and less efficient. This work aims to investigate the effect of the breathing phase number on the 4D robust optimization for pancreatic cancer intensity modulated proton therapy (IMPT) by examining plan quality